As of Sep 22
| +0.16 / +0.33%|
The 30 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 48.87, with a high estimate of 56.06 and a low estimate of 32.44. The median estimate represents a -0.71% decrease from the last price of 49.22.
The current consensus among 31 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since September, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.